TScan Therapeutics, Inc. 8K

TScan Therapeutics reported Q2 2026 results, announced progress across its TCR-T pipeline including initiation of a Phase 3 pivotal trial, and disclosed a cash runway into Q2 2027 under revised debt amortization terms.

On August 12, 2026, TScan Therapeutics, Inc. reported its financial results for the quarter ended June 30, 2026 and provided a corporate update, highlighting initiation of dosing in its Phase 3 ALLOHA-2 pivotal trial of TSC-101 in heme malignancies with topline data expected mid-2028, positive initial manufacturing and clinical data from Cohort C of its Phase 1 ALLOHA trial, an agreement with Cellares to evaluate automated cell-therapy manufacturing platforms, advancement plans for additional heme, solid tumor, and autoimmunity programs, and a cash position of $100.2 million expected to fund operations into the second quarter of 2027 under an updated debt amortization schedule triggered by missing certain non-covenant-related milestones.

Filing Facts

CIK

1783328

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-345732

Alert Tier

6